Plant · Scientific monograph
Vitis vinifera
Grape / Grape Seed Extract
For educational and scientific research only. Not medical advice. Independently verify claims against the cited primary sources. Consult a qualified healthcare professional before using any plant or fungal preparation.
Research areas: Cardiovascular System, Oxidative Stress Research, Blood Pressure Mechanisms, Venous & Peripheral Circulation
Research overview
Historical use
Grape seeds have been present in Mediterranean viticulture for over 6,000 years, though their deliberate medicinal use as a seed extract is a modern development. Traditional European viticulture regarded grape skins and seeds as by-products of wine production. The French paradox — the observation that wine-drinking Mediterranean populations showed lower cardiovascular mortality despite high saturated fat intake — prompted systematic investigation of grape polyphenols in the 1980s and 1990s. Grape seed proanthocyanidin extracts (GSPE) were subsequently standardised for pharmaceutical and nutraceutical use, with OPC-rich preparations achieving regulatory recognition in France as phlebotonics for venous insufficiency.
Modern research context
Grape seed extract standardised to oligomeric proanthocyanidins (OPCs, ≥95%) is among the most extensively studied botanical antioxidants in clinical cardiovascular research. A 2016 meta-analysis of 16 randomised controlled trials (n=810) found grape seed extract produced a significant mean reduction in systolic BP of 6.1 mmHg and diastolic BP of 2.8 mmHg, with the greatest effect in younger and obese participants [1]. (Note: individual constituent trials within this meta-analysis were labelled 'grape seed extract'; species-level confirmation of all 16 trials as exclusively Vitis vinifera was not verifiable from the published abstract.) A 2019 randomised, double-blind, placebo-controlled trial in prehypertensive adults (n=30, aged 40–64) demonstrated that high-dose GSPE (400 mg/day, 12 weeks) significantly reduced systolic BP by 13 mmHg and improved vascular stiffness parameters in non-smokers [2]. A 2021 randomised, double-blind, placebo-controlled trial (Enovita standardised V. vinifera seed extract, 300 mg/day, 16 weeks; exact n not reported in the published abstract) in healthy volunteers confirmed blood pressure modulation and reductions in perceived stress scores; reductions in endothelin-1 and soluble ICAM-1 were observed in complementary in vitro endothelial cell experiments reported within the same study [3]. A 2022 non-randomised pilot study (n=23) in patients with chronic venous insufficiency found that combined compression stocking and GSPE therapy produced a statistically significant increase in inferior vena cava peak blood flow velocity (P < 0.001), whereas stocking therapy alone did not reach significance; GSPE dose and duration for this trial were not reported in the published abstract [4].
Adverse effects
No serious adverse events were reported in the randomised controlled trials cited in this monograph, which used doses up to 400 mg/day for up to 16 weeks. Adverse effects reported in the broader clinical literature include dry or itchy scalp, dizziness, headache, nausea, and indigestion; these are not documented in the five primary references cited here and derive from the wider published GSE tolerability literature. Antiplatelet activity has been reported with grape seed OPC preparations, which may increase bleeding tendency; a specific dose threshold for this effect in humans has not been established in controlled trials. Long-term safety data beyond 16 weeks from well-controlled human trials are limited.
Contraindications
Exercise caution with anticoagulant and antiplatelet medications (warfarin, aspirin, clopidogrel, NSAIDs) due to additive antiplatelet activity of OPCs. Insufficient safety data exist for use during pregnancy and lactation; avoid medicinal-dose preparations in these populations. Patients with known hypersensitivity to grape or grape derivatives should avoid Vitis vinifera seed preparations.
Clinical and phytochemical data
Used part
Seed (grape seed extract, standardised to ≥95% OPC content)
Primary active compounds
Oligomeric proanthocyanidins (OPCs) — procyanidins B1, B2, B3, B4 (dimers and trimers of catechin/epicatechin)
Procyanidin C1 (trimer)
Catechin (flavan-3-ol monomer)
Epicatechin (flavan-3-ol monomer)
Gallic acid and gallic acid esters (including epicatechin gallate)
Resveratrol (stilbene; minor component in seed extract)
Tocopherols (vitamin E isomers; present in seed oil fraction)
Mechanism of action
Grape seed OPCs exert cardiovascular protection through multiple convergent mechanisms. Direct free-radical scavenging targets reactive oxygen species (ROS) and reactive nitrogen species; OPC oligomers are among the most potent plant-derived antioxidants by ORAC assay. Anti-inflammatory activity is mediated through suppression of NF-κB signalling: OPCs inhibit IκBα phosphorylation and p65 nuclear translocation, reducing downstream expression of pro-inflammatory cytokines (TNF-α, IL-1β, IL-6), COX-2, and cell adhesion molecules (ICAM-1, VCAM-1) on vascular endothelium (demonstrated in vitro in cultured human endothelial cells [3]). Endothelial vasoprotection involves upregulation of eNOS (endothelial nitric oxide synthase) via the AMPK/SIRT1/KLF2 pathway, increasing nitric oxide bioavailability and promoting vasodilation; simultaneous suppression of endothelin-1 (ET-1) reduces vasoconstrictor tone (in vitro, within the same study [3]). Antioxidant defence is further reinforced through activation of the Nrf2/HO-1 pathway, upregulating endogenous antioxidant enzymes (superoxide dismutase, glutathione peroxidase, catalase) — demonstrated in preclinical models; supporting citation not included in this monograph's primary reference set. OPCs also modulate platelet aggregation through effects on PECAM-1 (platelet/endothelial cell adhesion molecule-1) signalling, based on preclinical data; supporting citation not included in this monograph's primary reference set. Venous tone enhancement through collagen cross-link stabilisation and inhibition of collagenase/elastase activity is postulated as a mechanism underlying phlebotonic effects in venous insufficiency.
Pharmacokinetics
Absorption
Limited human pharmacokinetic data are available for grape seed OPCs. In a controlled human study (n=4 healthy volunteers), oral administration of 2.0 g of proanthocyanidin-rich grape seed extract resulted in detection of procyanidin B1 in serum at 2 hours post-dose at a mean concentration of 10.6 ± 2.5 nmol/L, demonstrating systemic absorption of intact dimeric proanthocyanidins [5]. The very small sample size (n=4) limits the generalisability of these findings. Monomeric flavan-3-ols (catechin, epicatechin) are absorbed more readily in the small intestine than higher-molecular-weight oligomers, which are poorly absorbed intact and undergo substantial colonic microbial catabolism prior to absorption. Overall oral bioavailability is low-to-moderate and highly dependent on molecular weight, gut transit time, and microbiome composition.
Distribution
No formal human pharmacokinetic distribution studies are available for Vitis vinifera seed extract OPCs beyond the serum detection reported in the n=4 pilot study [5]. In animal models, OPCs and their phenolic acid metabolites distribute to vascular endothelium, liver, kidney, and intestinal wall. Plasma protein binding of monomeric catechins is estimated at 60–70% in vitro. Volume-of-distribution data in humans have not been published for the OPC fraction.
Metabolism
Grape seed OPCs undergo two-phase metabolism. Higher-molecular-weight proanthocyanidins are hydrolysed by colonic microbiota to monomeric flavan-3-ols, which are further catabolised to hydroxyphenylpropionic acid, hydroxyphenylacetic acid, and hydroxyphenylvaleric acid derivatives — the dominant circulating and urinary metabolites in humans. Monomeric catechin and epicatechin undergo hepatic Phase II conjugation (glucuronidation, sulfation, O-methylation via COMT). No significant inhibition of CYP450 isoforms has been reported for grape seed OPCs at clinical supplemental doses.
Excretion
Phenolic acid metabolites of grape seed OPC catabolism are excreted primarily in urine, confirmed by human dietary intervention studies showing significant increases in urinary 3-hydroxyphenylpropionic acid (3-HPP) excretion following grape seed polyphenol intake. Biliary excretion of glucuronide conjugates contributes to faecal elimination. Exact elimination half-lives for specific OPC monomers and dimers in humans have not been established.
Safety and interactions
Drug interactions
Anticoagulants (warfarin) and antiplatelet agents (aspirin, clopidogrel, NSAIDs): additive antiplatelet activity via PECAM-1 modulation is mechanistically plausible; pharmacodynamic interaction cannot be excluded, though no clinically documented pharmacokinetic INR-altering interaction specific to grape seed extract has been identified in the reviewed literature. CYP450 interactions: no significant CYP inhibition has been documented at clinical doses in human studies; pharmacokinetic interactions with CYP substrates appear low-risk at standard supplemental doses. Additive antihypertensive effects are possible when combined with blood pressure-lowering medications; monitor blood pressure accordingly [1, 2, 3].
Toxicity
In 90-day rodent oral toxicity studies (regulatory preclinical safety literature; not directly cited in this monograph's five primary references), grape seed extract demonstrated a no-observed-adverse-effect level (NOAEL) of approximately 1,400–1,500 mg/kg/day. No evidence of mutagenicity was found in bacterial reverse mutation assays (regulatory preclinical data). No serious adverse events were reported in any of the clinical trials cited in this monograph. Grape seed extract preparations standardised to ≥95% OPCs are generally well tolerated in short-term trials up to 16 weeks; available clinical evidence does not support a significant hepatotoxic or nephrotoxic risk at supplemental doses up to 400 mg/day.
Special precautions
Pregnancy
Insufficient human safety data for medicinal-dose grape seed extract preparations during pregnancy. Animal studies have not identified teratogenic effects of OPCs at standard doses, but adequate human data are lacking. Avoid medicinal-dose preparations during pregnancy as a precautionary measure.
Lactation
Excretion of OPC metabolites into breast milk is unknown. Insufficient safety data for medicinal-dose preparations during lactation. Avoid as a precautionary measure.
Hepatic impairment
No formal studies in patients with hepatic impairment. Phase II hepatic conjugation is the primary metabolic route for monomeric catechin metabolites; impaired liver function may alter OPC metabolite clearance. Grape seed extract has not been associated with hepatotoxicity in available clinical data. Use with caution in severe hepatic impairment; no dose adjustment guidelines have been established.
Renal impairment
Primary elimination route for OPC-derived metabolites is renal. Accumulation of phenolic acid metabolites is possible in severe renal impairment. No specific adverse renal outcomes have been documented at supplemental doses in available clinical data. No dose adjustment guidelines have been established; use with caution in severe renal impairment.
Sources and references
- [1] - Zhang H et al. The impact of grape seed extract treatment on blood pressure changes: A meta-analysis of 16 randomized controlled trials. Medicine (Baltimore), 2016. PMID: 27537554
- [2] - Odai T et al. Effects of Grape Seed Proanthocyanidin Extract on Vascular Endothelial Function in Participants with Prehypertension. Nutrients, 2019. PMID: 31757033
- [3] - Schon C et al. Grape Seed Extract Positively Modulates Blood Pressure and Perceived Stress: A Randomized, Double-Blind, Placebo-Controlled Study in Healthy Volunteers. Nutrients, 2021. PMID: 33671310
- [4] - Jung HJ, Choo KS. Pilot study on the effect of grape seed proanthocyanidin extract on inferior vena cava blood flow in patients with chronic venous insufficiency using 4D flow MRI. Medicine (Baltimore), 2022. PMID: 36401399
- [5] - Sano A et al. Procyanidin B1 is detected in human serum after intake of proanthocyanidin-rich grape seed extract. Biosci Biotechnol Biochem, 2003. PMID: 12834296